

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

| | |
|------------------------|-----------------|
| Application Number | 10/825,282 |
| Filing Date | April 14, 2004 |
| First Named Inventor | Donald Bellgrau |
| Art Unit | 1633 |
| Examiner Name | Sumesh Kaushal |
| Attorney Docket Number | 3921-1-1-1-1 |

Sheet 1 of 3

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number-kind Code ^{2 (if known)} | Publication Date MM-DD-YYYY | Name of Patentee of Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|-----------------------------|---|---|
| | 1 | 5109580 | 05/05/92 | Blanco et al. | |
| | 2 | 5183058 | 02/02/93 | Janese | |
| | 3 | 5759536 | 06/02/98 | Bellgrau et al. | |
| | 4 | 6325999 | 12/04/01 | Bellgrau et al. | |
| | 5 | 08/250478 | | Bellgrau et al. (05/27/94) | |
| | 6 | 09/456357 | | Bellgrau et al. (12/8/99) | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ^{5 (if known)} | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|-----------------------------|---|---|-----------------------|
| | 7 | WO 95/13293 | 05/18/95 | Mochida Pharm Co LTD | | (translated abstract) |
| | 8 | WO 99/13073 | 03/18/99 | RPR Gencell Asia Pacific Inc. | | |

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

| Examiner Initials* | Cite No. ¹ | |
|--------------------|-----------------------|---|
| | 9 | Anderson, W. French, Human Gene Therapy, Nature Vol 392, Supp, April 30, 1998 |
| | 10 | Friedmann, Theodore, Principles for Human Gene Therapy Studies, Vol 287, March 2000 |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

| | |
|------------------------|-----------------|
| Application Number | 10/825,282 |
| Filing Date | April 14, 2004 |
| First Named Inventor | Donald Bellgrau |
| Art Unit | 1633 |
| Examiner Name | Sumesh Kaushal |
| Attorney Docket Number | 3921-1-1-1-1 |

| | | | |
|-------|---|----|---|
| Sheet | 2 | of | 3 |
|-------|---|----|---|

| | |
|----|---|
| 11 | Johnstone & Thorpe, "Immunochemistry in Practice", by Blackwell Scientific Publications, Oxford, (1987) pp. 30-47 |
| 12 | Lynch, et al., "Fas and FasL in the homeostatic regulation of immune responses, "Immunology Today, vol. 16, no. 12, December 1995, pages 569-574 |
| 13 | MOUNTZ, "Autoimmune disease," Arthritis & Rheumatism, vol. 37, no. 10, October 1994, pages 1415-1420 |
| 14 | Nagata et al. "The Fas Death Factor," (1995) Science 267:1449-1456 |
| 15 | Nagata, "Fas and Fas Ligand: A Death factor and its receptor," Adv. Immunol. Vol. 57, 1994, pages 129-144 |
| 16 | Nagata, Shigekazu et al, The Fas Death Factor, Science, Volume 267, March 10, 1995, pages 1449-1456 |
| 17 | SMITH et al., "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death," Cell, Vol. 76, 959-962, March 25, 1994 |
| 18 | Suda & Nagata, "Purification and Characterization of the Fas-ligand that induces Apoptosis," J. Exp. Med. Vol. 179, March 1994, pages 873-879 |
| 19 | Varmus, Harold , Gene therapy: Not ready for prime time, Nature Medicine, Volume 2, January 1, 1996 |
| 20 | Verma, Inder M. et al, Gene therapy promises, problems and prospects, Nature Vol 389, September 18, 1997 |
| 21 | Verma, Inder M. , "Gene Therapy: beyond 2000," Molecular Therapy Vol. 1, No.6, June 2000 |
| 22 | Notice of Reasons for Rejections for Japanese Application No. 08-501092, dated November 25, 2005 (Attorney's Reference No. 2848-20-PJP) |
| 23 | Notice of Reasons for Rejections for Japanese Application No. 08-501092, dated September 26, 2006 (Attorney's Reference No. 2848-20-PJP) |
| 24 | Decision to Grant a Patent for Japanese Patent Application No. Hei 8-501092, dated March 23, 2007 (Attorney's Reference No. 2848-20-PJP) |
| 25 | Official Action for European Application No. 95921459.4, dated June 5, 2003 (Attorney's Reference No. 3921-1-PEP) |
| 26 | Official Action for European Application No. 95921459.4, dated February 17, 2004 (Attorney's Reference No. 3921-1-PEP) |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

| | |
|------------------------|-----------------|
| Application Number | 10/825,282 |
| Filing Date | April 14, 2004 |
| First Named Inventor | Donald Bellgrau |
| Art Unit | 1633 |
| Examiner Name | Sumesh Kaushal |
| Attorney Docket Number | 3921-1-1-1-1 |

| | | | |
|-------|---|----|---|
| Sheet | 3 | of | 3 |
|-------|---|----|---|

| | | |
|--|----|---|
| | 27 | Official Action for European Application No. 95921459.4, dated February 10, 2006 (Attorney's Reference No. 3921-1-PEP) |
| | 28 | Official Action for Canadian Patent Application No. 2,189,778, dated September 25, 2009 (Attorney's Reference No. 3921-1-PCA) |
| | 29 | Official Action for Canadian Patent Application No. 2,189,778, dated January 3, 2008 (Attorney's Reference No. 3921-1-PCA) |
| | 30 | Official Action for Australian Patent Application No. 26535/95, dated January 2, 1998 (Attorney's Reference No. 3921-1-PAU) |
| | 31 | Official Action for Australian Patent Application No. 26535/95, dated May 27, 1999 (Attorney's Reference No. 3921-1-PAU) |
| | 32 | Notice of Acceptance for Australian Patent Application No. 26535/95, dated November 24, 1999 (Attorney's Reference No. 3921-1-PAU) |
| | 33 | Supplementary European Search Report for European Application No. 95921459.4, dated April 3, 1998 (Attorney's Reference No. 3921-1-PEP) |
| | 34 | Supplementary European Search Report for European Application No. 95921459.4, dated April 22, 1999 (Attorney's Reference No. 3921-1-PEP) |
| | 35 | International Preliminary Examination Report for International (PCT) Application No. PCT/US95/06742, mailed September 3, 1996 |
| | 36 | International Search Report for International (PCT) Application No. PCT/US95/06742, mailed August 5, 1995 |
| | 37 | Written Opinion for International (PCT) Application No. PCT/US95/06742, mailed August 5, 1995 |
| | 38 | Kang et al., "Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction," 1997, Nature Med. 3:738-743 |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.